Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Not yet recruiting 3Recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 926Neoplasms 609Breast Neoplasms 604Colorectal Neoplasms 457Neoplasm Metastasis 394Ovarian Neoplasms 328Melanoma 312Prostatic Neoplasms 311Lung Neoplasms 294Multiple Myeloma 290Recurrence 278Squamous Cell Carcinoma of Head and Neck 246Stomach Neoplasms 229Pancreatic Neoplasms 228Leukemia, Myeloid, Acute 220Triple Negative Breast Neoplasms 190Endometrial Neoplasms 190Carcinoma, Renal Cell 182Lymphoma, Non-Hodgkin 179Carcinoma, Hepatocellular 177Small Cell Lung Carcinoma 165Leukemia, Lymphocytic, Chronic, B-Cell 156Advanced Solid Tumors 154Lymphoma, Follicular 148Urinary Bladder Neoplasms 139Lymphoma, Large B-Cell, Diffuse 138Lymphoma 137Advanced Solid Tumor 137Uterine Cervical Neoplasms 134Head and Neck Neoplasms 134

Interventions

pembrolizumab 1Lutetium-177 1Lutetium 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Castration-resistant Prostate Cancer (mCRPC) × 1 year × Clear all
NCT07310355 2025-12-30

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Chengdu StarRay Therapeutics Co., Ltd

Phase 1/2 Not yet recruiting
49 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07244393 2025-11-24

Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer

Cellbion Co., Ltd.

Phase 1 Not yet recruiting
30 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT06241846 2025-08-27

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT07104617 2025-08-05

Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

TYK Medicines, Inc

Phase 1/2 Not yet recruiting
48 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡